Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.

Abstract: A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of same in preparation of a drug for preventing and/or treating diseases or conditions associated with HPK1 activity.

Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.

Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.

Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.

Abstract: Provided is an oxygen-substituted six-membered ring pyrimidine compound with selective inhibitory effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, as represented by formula (I). The definition of each group or symbol in the formula is detailed in the specification. Moreover, a pharmaceutical composition containing the compound and an application thereof in the preparation of cancer drugs are also provided.

Abstract: An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.

Abstract: The present invention relates to a 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative substituted by N-(3-aminophenyl)acrylamide and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and a preparation method and application of the same. The definition of each substituent in the formula is described in detail in the specification and claims.

Abstract: The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.

Abstract: The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.

Abstract: The present invention relates to a 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative substituted by N-(3-aminophenyl)acrylamide and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and a preparation method and application of the same. The definition of each substituent in the formula is described in detail in the specification and claims.

Abstract: The present invention provides an electromagnetic interference suppression circuit including an isolation module, a transient high voltage suppression module, a common mode rejection module, and a filter module. The isolation module electrically isolates first signals to generate second signals. The transient high voltage suppression module protects the second signals against overvoltage spikes. The common mode rejection module protects the second signals against common mode noise. The filter module filters noise of the second signals, and protects the second signals against signal reflection at output terminals of the electromagnetic interference suppression circuit. The present invention further provides an electric vehicle including the electromagnetic interference suppression circuit.

Abstract: A combo communication terminal has a first communication terminal and a second communication terminal. A switch unit of the second communication terminal has a first end, a second end, a third end and a control end. The control end selectively couples the first end to the second end or to the third end according to a control signal. When a communication link between the first communication terminal and the second communication terminal has been established, a second processing unit of the second communication terminal generates and transmits a first control signal to the control end, such that a first processing unit of the first communication terminal is coupled to a first subscriber identity unit of the second communication terminal via the first port, so that the first communication terminal uses the first subscriber identity unit to perform tasks of communication.

Abstract: A combo communication terminal has a first communication terminal and a second communication terminal. A switch unit of the second communication terminal has a first end, a second end, a third end and a control end. The control end selectively couples the first end to the second end or to the third end according to a control signal. When a communication link between the first communication terminal and the second communication terminal has been established, a second processing unit of the second communication terminal generates and transmits a first control signal to the control end, such that a first processing unit of the first communication terminal is coupled to a first subscriber identity unit of the second communication terminal via the first port, so that the first communication terminal uses the first subscriber identity unit to perform tasks of communication.